NCT00250978View on ClinicalTrials.gov

Ph I:Bevacizumab + Chemotherapy in Pts w/Malig Pleural Effusion Due to Adv NSCLC

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

bevacizumab with chemotherapy, Pleur-XTM catheter placement

After Pleur-XTM catheter placement patients will receive bevacizumab 15mg/kg IV x 1 dose as a single agent.Three weeks later, chemotherapy will be initiated according to routine clinical practice along with continued use of bevacizumab.

Trial Locations (1)

10021

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00250978 - Ph I:Bevacizumab + Chemotherapy in Pts w/Malig Pleural Effusion Due to Adv NSCLC | Biotech Hunter | Biotech Hunter